The stock of Lantheus Holdings Inc (NASDAQ:LNTH) is a huge mover today! About 241,793 shares traded hands. Lantheus Holdings Inc (NASDAQ:LNTH) has risen 266.37% since March 7, 2016 and is uptrending. It has outperformed by 258.78% the S&P500.
The move comes after 8 months negative chart setup for the $291.21 million company. It was reported on Oct, 10 by Barchart.com. We have $6.94 PT which if reached, will make NASDAQ:LNTH worth $40.77M less.
Analysts await Lantheus Holdings Inc (NASDAQ:LNTH) to report earnings on November, 2. They expect $0.07 EPS, down 61.11% or $0.11 from last year’s $0.18 per share. LNTH’s profit will be $2.53M for 28.82 P/E if the $0.07 EPS becomes a reality. After $0.24 actual EPS reported by Lantheus Holdings Inc for the previous quarter, Wall Street now forecasts -70.83% negative EPS growth.
Lantheus Holdings Inc (NASDAQ:LNTH) Ratings Coverage
Out of 5 analysts covering Lantheus Holdings (NASDAQ:LNTH), 2 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 40% are positive. Lantheus Holdings has been the topic of 9 analyst reports since August 31, 2015 according to StockzIntelligence Inc. As per Monday, August 31, the company rating was downgraded by Robert W. Baird. Wells Fargo downgraded the stock to “Market Perform” rating in Wednesday, September 30 report. The stock of Lantheus Holdings Inc (NASDAQ:LNTH) earned “Neutral” rating by Credit Suisse on Friday, December 11. The rating was initiated by Credit Suisse with “Neutral” on Friday, September 23. The rating was maintained by RBC Capital Markets with “Outperform” on Wednesday, February 24. The stock of Lantheus Holdings Inc (NASDAQ:LNTH) has “Buy” rating given on Monday, August 29 by Jefferies.
According to Zacks Investment Research, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States.”
More important recent Lantheus Holdings Inc (NASDAQ:LNTH) news were published by: Fool.com which released: “Why Lantheus Holdings Inc. Sold Lower Friday” on September 09, 2016, also Businesswire.com published article titled: “Lantheus Holdings, Inc. Announces Public Offering of 5200000 Shares of Common …”, Businesswire.com published: “Lantheus Holdings, Inc. to Present at Upcoming Investor Conferences” on August 24, 2016. More interesting news about Lantheus Holdings Inc (NASDAQ:LNTH) was released by: Businesswire.com and their article: “Lantheus Holdings, Inc. Reports 2016 Second Quarter Financial Results” with publication date: August 04, 2016.
LNTH Company Profile
Lantheus Holdings, Inc., incorporated on November 30, 2007, develops, makes and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities. The Company’s contrast agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging or magnetic resonance imaging (MRI), which are used by physicians to progress the clarity of the diagnostic image. Radiopharmaceuticals are radioactive pharmaceuticals used by clinicians to perform nuclear imaging procedures. The Company’s imaging agents include contrast agents and medical radiopharmaceuticals (including technetium generators), including DEFINITY, TechneLite, Xenon Xe 133 Gas (Xenon), Cardiolite and Neurolite.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.